C01AA05 digoxin
CARDIOVASCULAR SYSTEM ›CARDIAC THERAPY ›CARDIAC GLYCOSIDES ›Digitalis glycosides
健保收載品項 FDA 已核准 TFDA 在效許可證 3 健保給付條款 1
健保收載品名："中外" 長葉毛地黃?注射液０．２５公絲/公撮、"晟德" 地高新酏劑 50 微公絲/公撮、"順華"長葉毛地黃注射液、Digosin tab 0.25mg、力扶心片、山德士－狄各新錠、山德士－狄各新錠０．２５公絲、毛地黃異素錠、治強片、自固心酏、致固心錠 〝順華〞、長葉毛地黃/錠、長葉毛地黃/錠０．２５公絲、長葉毛地黃/錠０．２５ＭＧ、隆我心注射劑、隆我心錠
FDA 適應症
1 INDICATIONS AND USAGE Digoxin is a cardiac glycoside indicated for: • Treatment of mild to moderate heart failure in adults (1.1) . • Increasing myocardial contractility in pediatric patients with heart failure (1.2). • Control of resting ventricular rate in patients with chronic atrial fibrillation in adults (1.3). 1.1 Heart Failure in Adults Digoxin is indicated for the treatment of mild to moderate heart failure in adults. Digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. Where possible, digoxin should be used in combination with a diuretic and an angiotensin-converting enzyme (ACE) inhibitor. 1.2 Heart Failure in Pediatric Patients Digoxin increases myocardial contractility in pediatric patients with heart failure. 1.3 Atrial Fibrillation in Adults Digoxin is indicated for the control of ventricular response rate in adult patients with chronic atrial fibrillation.
資料來源：openFDA（美國 FDA Structured Product Labeling）。為英文原文，僅供對照。
TFDA 適應症
NHI 給付規定
直接適用條款
§ 2.15 Digoxin 口服液劑(如Cardiacin elixir)：(110/1/1)
心臟血管及腎臟藥物 › Digoxin 口服液劑(如Cardiacin elixir)：(110/1/1)
Digoxin口服液劑(如Cardiacin elixir)：(110/1/1) 限用於年齡1個月以上至未滿7歲兒童。
歷史演變（1 次異動）
| 生效日 | 異動說明 |
|---|---|
| 110/1/1 | legacy_boan_parsed:ch02.txt |
實證補充
本藥品尚無實證補充整理（未來新增 Review／指引知識時補列）。
FDA 段：openFDA US SPL · TFDA 段：食藥署西藥許可證＋ATC 分類開放資料 · NHI 段：健保署「全民健康保險藥品給付規定」（更新日 2026-05-31）· 實證補充段：人工彙整。 本頁為資訊整理，實際給付與適應症以主管機關公告為準。